InvestorsHub Logo
Followers 532
Posts 31795
Boards Moderated 2
Alias Born 09/23/2010

Re: None

Tuesday, 02/21/2017 3:06:09 PM

Tuesday, February 21, 2017 3:06:09 PM

Post# of 15281
EQUR 0.2 FDA Approval 8k

Item 8.01 Other Events

On November 11, 2016, E-Qure Corp., a Delaware corporation (the "Registrant"), reported on Form 8-K that on October 14, 2016, the Registrant received notification from FDA that it had been granted conditional approval to the IDE application, authorizing the Registrant to commence a clinical investigation of our BST Device with 10 patients at a single site.

On February17, 2017, the Registrant received FDA's IDE approval letter which authorized the Registrant to begin a new 10-patient feasibility study to be conducted at up to 5 sites rather than the October 14, 2016 FDA approval for only one site. The FDA approval for expanding the study should expedite the Registrant's ability to enlist patients for the study. The Registrant plans to submit a safety report with the FDA following which we intend to proceed with a trial, which contemplates testing the BST Device with 90 patients.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.